The FDA has already approved DBS as a treatment for neurologic disorders, including essential tremor, Parkinson's disease,
dystonia, and severe obsessive-compulsive disorder. In the March 2005 Neuron, researchers Helen Mayberg, M.D., and colleagues initially reported six-month outcomes for six patients who received DBS
to the subcallosal cingulate gyrus (Brodmann's area 25) for treatment-resistant depression. They subsequently reported, in
the September 2008 Biological Psychiatry, on 12-month outcomes in an expanded sample of 20 patients (Psychiatric News, September 5, 2008).